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Abstract 
There are few effective pharmacological therapies available to treat refractory chronic cough.  
Functional MRI studies of the brain have recently shown that patients with chronic cough 
have dysfunctional inhibitory control of cough. Self-management therapies delivered by 
physiotherapists or speech therapists are effective at suppressing cough. They enable patients 
to consciously suppress the urge to cough. The intervention consists of education, laryngeal 
hygiene, cough suppression and distraction measures and behaviour modification. The 
efficacy of Physiotherapy and Speech And Language Intervention (PSALTI) has been 
confirmed in two randomised control trials.  In one trial, there was a 41% reduction in cough 
frequency with PSALTI, assessed objectively with the Leicester Cough Monitor, and a 
clinically significant improvement in quality of life. Importantly, the improvement in cough 
was sustained when therapy was discontinued. The addition of the Speech Pathology 
Treatment to neuromodulator drug therapy, Pregabalin has also been evaluated in a clinical 
trial. There was a clinically significant improvement in quality of life, and this was sustained 
when therapy was discontinued. The mechanism of action of PSALTI is not known and this 
should be investigated in future. Further studies are needed to identify the components of 
PSALTI that deliver the most benefit, and determine whether PSALTI is effective in cough 
associated with other chronic lung disorders. 
Keywords: Cough hypersensitivity syndrome, chronic cough, Physiotherapy, Speech and 
Language therapy, PSALTI.  
Funding: This work did not receive any specific grant from funding agencies in the public, 
commercial, or not-for-profit sectors. 
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1. Cough Hypersensitivity Syndrome and dysfunctional inhibitory control 
Chronic cough is defined as a cough persisting greater than eight weeks but in the specialist 
clinic setting, most patients have lived with this disorder for many years [1]. Adverse 
symptoms associated with cough are common such as urinary incontinence, syncope, chest 
pain and interference with speech [2,3]. Patients with chronic cough have a poor quality of 
life and often avoid social situations in which they feel embarrassed [4]. Chronic cough is 
thought to be a disorder of dysregulated sensory nerves that convey information about the air 
we breathe in to the brain, such as changes in temperature, humidity and the presence of 
airway irritants [5]. Patients are hypersensitive to airway irritants and this can be 
demonstrated in the laboratory with the Cough Challenge Test [6]. Capsaicin, the extract of 
chilli pepper is the most widely used tussive agent in such tests. The term “Cough 
Hypersensitivity Syndrome” (CHS) for chronic cough disorders has been proposed by the 
European Respiratory Society taskforce [7]. It is likely that this term encompasses patients 
with refractory, idiopathic and unexplained chronic cough. The activation of airway sensory 
nerves in CHS often results in a sensation called the urge to cough [8]. This can lead to a 
brain stem mediated reflex cough but, more often, it is processed in higher brain centres 
where it can be modulated to consciously suppress it or to generate a cough to relieve the 
urge [5]. An important recent finding is that patients are less able to suppress their cough; 
functional MRI imaging studies have shown reduced activity in the descending cortical motor 
inhibitory pathways [9]. 
 
There are few drug treatments available for patients with CHS [10]. Neuromodulator drugs 
such as Gabapentin, Pregabalin and Amitriptyline are effective in some patients [2,11–13]. It 
is likely that their mechanism of action is in the central nervous system and the side effects 
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also reflect this, such as drowsiness. There is a need for alternative therapeutic approaches.   
In a recent survey conducted by the European Lung Foundation, many patients expressed the 
need for self-management interventions [14]. PSALTIs have long been used to treat patients 
with chronic cough [15,16]. They consist of multiple components delivered in sessions by a 
therapist [17]. They include helping the patient to be in control of their cough, use cough 
suppression techniques and behaviour modification and relaxation therapies. This article 
reviews the emerging evidence for PSALTI for patients with CHS.  
 
2. PSALTI Components 
The components of PSALTI have been reviewed in detail elsewhere and summarised in 
Table 1 [18]. Briefly, the therapy starts by educating patients about chronic cough and the 
concept of cough reflex hypersensitivity. Patients are informed about their ability to 
consciously control cough, and also the negative effects of repeated coughing.  They are then 
taught cough suppression and distraction techniques, such as forced swallowing, sipping 
water and sucking sweets.  They are asked to identify the triggers of their cough and the urge 
to cough, so they apply the cough suppression methods in these specific situations.  
Dysfunctional breathing patterns are common in CHS. These patients generally adopt a 
mouth breathing pattern which we believe is a significant influencing factor in CHS.  
Furthermore, vocal cord dysfunction (VCD) can also coexist in CHS and can be 
demonstrated objectively by visualising the vocal cords under conditions designed to reveal 
abnormal movements [19]. Therefore, breathing pattern retraining and vocal cord exercises 
are thought to be an important component of cough management. Psycho-educational 
counselling is used to motivate patients, and to modify behaviour to reduce an over-
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awareness of the need to cough. Lastly, interventions that relieve stress and anxiety are 
recommended where appropriate. 
 
The optimal number of sessions of therapy, their duration and frequency are not known. In 
clinical trials, four sessions of therapy have been delivered over one or two months [18,20]. 
The duration of sessions in one trial were initially one hour, followed by 30-45 minutes for 
subsequent sessions. Whilst PSALTI is a standardised therapy, it has the flexibility to be 
individually tailored to the patient’s needs. It is important that therapists receive training to be 
able to deliver effective therapy. The delivery of PSALTI can be facilitated by the use of 
written treatment plans and educational material [18].  
 
2.1 The Evidence 
In 2006, Vertigan et al [20] was the first to demonstrate that speech therapy was effective at 
reducing cough in a single specialist centre randomised control trial. There was a reduction in 
the severity of cough in 87% of patients. In 2011, Patel et al [21] reported a significant 
reduction in the severity of cough, with a physiotherapy-led intervention, but this study did 
not include a control group for comparison. Patel et al [21] reported 70% of patients had an 
improvement in health status with PSALTI greater than the minimal clinically important 
difference of the Leicester Cough Questionnaire [4]. Recently, Chamberlain-Mitchell et al 
[18] evaluated PSATLI in chronic refractory cough in a randomised controlled trial. This was 
a multi-centre trial that comprised both secondary care and tertiary care sites. The therapy 
was delivered by either a specialist physiotherapist or a speech therapist. Patients underwent 
weekly sessions over four weeks. The control intervention was healthy lifestyle advice that 
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was delivered in a similar number of sessions, to ensure that patients received equal attention.   
The primary outcome measure was health-related quality of life assessed with the validated 
Leicester Cough Questionnaire [18]. Secondary outcomes included cough frequency 
measured with the validated Leicester Cough Monitor and capsaicin cough reflex sensitivity 
[22]. PSALTI was associated with a clinically significant improvement in cough-specific 
quality of life after adjusting for changes with the control intervention. There was a 41% 
reduction in objective cough frequency, compared to the control intervention; this was 
considered clinically significant [18]. There was a significant reduction in cough reflex 
sensitivity with PSALTI, but this was not significant after adjusting for the reduction with the 
control intervention. An important observation from this trial was that improvement in cough 
with PSALTI was sustained following completion of therapy at a three-month follow-up 
visit. The key strengths of this trial were that it was multi-centre, multi-disciplinary, inclusion 
of specialist and non-specialist centres and the use of validated objective and subjective 
cough end-points. There were no side effects associated with therapy.  
   
2.2 How Does It Work? 
The mechanism of action of PSALTI is not known. Recent functional-MRI brain studies have 
reported dysfunctional inhibitory control in patients with CHS [9]. One explanation could be 
that by practicing cough suppression techniques, patients restore their control over cough.  In 
a post-hoc analysis of PSALTI trial reported by Chamberlain Mitchell S et al [24], patients 
with evidence of dysfunctional breathing at baseline responded best to PSALTI. 
Dysfunctional breathing patterns, if present, may dehydrate and irritate the larynx and 
activate cough receptors. Therefore breathing exercises may reduce the stimulus to cough. 
PSALTI also reduces the sensitivity of the cough reflex [25]. This is likely to be a 
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consequence of the interventions and also due to breaking the cycle of cough exacerbating 
further coughing. It is noteworthy that the lifestyle interventions used as control therapy in 
clinical trials had a beneficial effect in reducing cough [18]. Lifestyle advice to reduce stress 
and anxiety is an important component of PSALTI therapy. The efficacy of PSALTI 
therefore is likely to be greater than that reported in trials since it was compared to an active 
intervention, rather than a true placebo.   
 
2.3 Patient Selection 
Clinical trials of PSALTI have typically included patients with a chronic, refractory cough.   
These are patients who have undergone detailed investigations and trials of treatment for 
associated aggravants, such as asthma, gastro-oesophageal reflux disease and rhinitis. There 
are currently no investigations available that diagnose CHS. The clinical profile of patients is 
helpful. They are more likely to be female with an onset of cough between age 40 to 60 years 
old [26]. Patients usually have a dry or minimally productive cough. A detailed cough 
symptom history is helpful. Cough may triggered by typical tussive stimuli, such as strong 
odours (hypertussia) and non-tussive stimuli, such as talking, laughing and easting certain 
foods (allotussia) [27]. Most patients report a sensation of the urge to cough sensation.   
Abnormal laryngeal sensations are common such a tickly throat (laryngeal paraesthesia) [27]. 
The Cough Hypersensitivity Questionnaire (CHQ) records the triggers of cough and 
associated symptoms [28]. Further studies are needed to investigate its potential to identify 
patients who improve with PSALTI. The Newcastle Laryngeal Hypersensitivity 
Questionnaire, although developed for patients with Laryngeal Hypersensitivity, is another 
tool that deserves further study since many patients with Laryngeal Hypersensitivity present 
with cough [29].  
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2.4 Adherence 
Adherence is discussed during each PSALTI session and patients are encouraged to be 
compliant with therapy. The adherence to PSALTI in previous trials is not known. There is 
no gold standard outcome measure of self-reported adherence [23]. Cough physiotherapy is a 
complex intervention, where measuring adherence to each specific component is 
unattainable. For specific interventions, such as breathing retraining or vocal cord exercises, 
patients can simply record the frequency and duration of doing these exercises. However, the 
poor validity of such an approach needs to be acknowledged. Therefore, rather than asking 
patients to measure their adherence with the intervention, it may be more advantageous to ask 
patients to keep diaries to document the impact of the therapy on their symptom. This 
approach may help motivate patients to be more adherent with the therapy. 
 
2.5 Who Should Deliver PSALTI? 
PSALTI has been delivered by either Speech and Language or Voice Therapists or 
Physiotherapists. There is evidence to support the efficacy of cough suppression interventions 
delivered by either therapist [20,21]. The PSALTI trial included centres that delivered speech 
and physiotherapy led interventions [18]. There was no effect of either the type of therapist or 
centre on the efficacy of PSALTI [18]. It is important that therapists receive training in cough 
suppression, and that they follow a standardised protocol. The choice of therapist is likely to 
be dictated by their availability locally. It is important that Physiotherapists and Speech 
Therapists work together to improve the availability of this therapy and to achieve the 
common goal of improving the quality of life of patients with cough. The development of 
treatment guidelines, patient information leaflets and creation of specialist therapist interest 
support groups may facilitate this. 
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2.6 Cost Of Therapy 
At King’s College Hospital London, the cost of PSALTI is £323.28 per patient in 2017 (4 
out-patient sessions). This compares favourably with an alternative therapy for refractory 
chronic cough, Gabapentin [11]. At King’s College Hospital, the cost of a 3-month trial of 
Gabapentin in 2017 is £471.42 per patient (1800 mg dose per day and 3 out-patient clinic 
visits for initiation and supervision). The cost of therapies for refractory chronic cough is 
likely to vary according to the health care setting and country. It is important to determine the 
cost-effectiveness of PSALTI using validated methods in future studies. 
 
2.7 Combination With Drug Therapy 
A recent trial by Vertigan et al [12] reported that the combination of speech therapy with 
neuromodulator drug therapy Pregabalin was associated with greater improvements in cough. 
There was a significantly greater increase in cough-specific quality of life in patients 
receiving speech therapy plus Pregabalin therapy compared to speech therapy alone.   
Importantly, the benefit of this combination therapy was sustained following its 
discontinuation when assessed at four months.  Further studies are needed to investigate the 
efficacy of PSALTI when combined with other anti-tussive therapies such as MK7264, a 
peripherally acting inhibitor of sensory nerve receptor P2X3 currently in clinical trials.  
 
3. Conclusion 
There is good quality evidence from randomised control trials to support the use of PSALTI 
in patients with Cough Hypersensitivity Syndrome. PSALTI reduces the frequency of cough, 
significantly improves quality of life and is associated with few or no side effects. When 
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combined with neuromodulator drug therapy, it is associated with greater improvements in 
cough. Further studies are needed to determine the components of PSALTI that are most 
effective, and also its cost-effectiveness. PSALTI can be delivered by either speech or 
physiotherapists. There is a need train therapists in PSALTI and to promote its utility 
amongst clinicians treating patients with cough. CHS can coexist with other chronic 
respiratory disorders such as asthma, chronic obstructive pulmonary disease, idiopathic 
pulmonary fibrosis and sarcoidosis and therefore the efficacy of PSALTI should be 
investigated in a wider context of patients suffering from a persistent cough.    
 
 
  
11	
	
	
	
Table 1. PSALTI components  
 
PSALTI 
component 
Technique 
Education Educate patients on chronic cough and cough reflex hypersensitivity. 
Explain the negative effects of repeated coughing 
Educate patients on voluntary control of cough 
Laryngeal 
hygiene and 
hydration 
Increase frequency and volume of water and non-caffeinated drinks 
Reduce caffeine and alcohol intake 
Promote nasal breathing 
Cough control Teach patients to identify their cough triggers 
Teach patients to use cough suppression or distraction techniques at 
the first sign or sensation of the need or urge to cough. These cough 
suppression/distraction techniques include: forced swallow, sipping 
water and sucking sweets. 
Teach patients breathing exercises: breathing pattern re-education 
promoting relaxed abdominal breathing pattern technique; pursed lip 
breathing to use to control cough. 
Psycho-
educational 
counselling 
Motivate patients, reiterate the techniques and the aims of therapy 
Behaviour modification: to try to reduce over-awareness of the need 
to cough 
Stress and anxiety management 
Modified from Chamberlain-Mitchell et al [18] 
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